were evaluated in the immunotherapy group. RESULTS: A total of 21 elderly patients with AML were included in the immunotherapy group and 23 in the control group. The clinical efficacy in the immunotherapy group was greater than in the control group. The percentages of T cell subsets and cytokine levels after immunotherapy treatment were significantly higher than before the treatment. CONCLUSION: Immuno therapy with autologous DCs and CIK cells was found to be a promising candidate for treatment of AML in elderly patients.
Introduction
In elderly patients with acute myeloid leukaemia (AML), 17% have a chromosome karyotype for poor prognosis and 57% have drug resistance gene expression accompanied by multiple diseases and poor physical condition compared with younger patients with AML. 1 Elderly patients with AML are less sensitive to chemotherapy, have higher mortality associated with chemotherapy, and cannot tolerate highdose chemotherapy and haemopoietic stem cell transplantation (HSCT); the median survival time is only 6 -9 months. 2 Cellular immunotherapy is a new and promising treatment for various cancers, with the advantages of killing leukaemia cells by means of different mechanisms and fewer adverse events than standard chemotherapy. 3, 4 Cellular immunotherapy has the ability to restore the body's natural immune system and can kill tumour cells directly or stimulate an immune response to kill tumour cells. This is done by transfusing ex vivo immune cells with antitumour activity into the patient. Dendritic cells (DCs) are major antigen-presenting cells (APCs) that recognize and present antigens to T cells, inducing an antitumour T cell effect. 5 Cytokine-induced killer (CIK) cells are immune effector cells that play a potential role in adoptive cell immunotherapy and exhibit potent cytotoxicity against a variety of autologous and allogeneic AML cells. 6 Thus, DCs present antigens to T cells initiating an antitumour response by activating cytotoxic T cells and CIK cells, which can kill tumour cells by acting on autologous cytotoxicity and secreting cytokines. 5, 7 Some in vivo and in vitro animal studies have reported that the combination of CIK cells with relevant chemotherapy enhanced antitumour effectiveness in human drug-resistant cancer cell lines and that this was not influenced by the multipledrug resistance of the tumour. 8, 9 In previous studies, venous transfusion of DCs and CIK cells was performed after complete haematological remission had occurred in order to mitigate the negative impact of chemotherapy and immunosuppression on the body's immune system response to DC and CIK cell therapy. 10, 11 Clinical efficacy and adverse reactions associated with venous transfusion of DCs and CIK cells from before complete remission throughout chemotherapy still needs to be studied further.
Autologous immune cell therapy has been approved in China as a class III medical technique for the application of clinical treatment and has been listed in the Chinese Medical Insurance Directory. The present study investigated the possibility of culturing DCs and CIK cells, obtained at initial diagnosis of AML in elderly patients, and investigated the safety and efficacy of autologous DCs and CIK cells combined with low-dose chemotherapy to treat elderly patients with AML. As a measure of the patients' immune response, T cell subsets and cytokine levels were evaluated. were assigned to the immunotherapy group based on their medical health insurance cover and whether or not they chose to undergo both immunotherapy and chemotherapy, otherwise they were assigned to the control group. Patients in both groups were followed up for 4 weeks after treatment.
Patients and methods

STUDY POPULATION AND TREATMENT GROUPS
Written, informed consent was obtained from patients or the patient's carer and the study was approved by the Medical Ethics Committee of The Affiliated Fourth Hospital of Harbin Medical University.
GENERATION OF DCs AND CIK CELLS
For patients in the immunotherapy group, blood was taken at the time of AML diagnosis for the generation of DCs and CIK cells. Before collecting blood for purification of peripheral blood mononuclear cells (PBMCs), haemograms were carried out. If the white blood cell count was ≤ 3.5 × 10 9 cells/l, 150 -300 µg of granulocytemacrophage colony-stimulating factor (GM-CSF; Kirin, Tokyo, Japan) was administered 12 h before acquisition to increase the white blood cell count to > 3.5 × 10 9 cells/l. If the haemoglobin level was ≤ 80 g/l, 2 -4 U of red blood cell suspension was administered before acquisition and, if platelets were ≤ 50 × 10 9 cells/l they were supplemented before acquisition. Blood collection was carried out after making sure that there were no abnormalities in body temperature, blood coagulation, liver and kidney function, and after examination of electrocardiogram and chest computed tomography images.
A COM.TEC ® blood cell separator (Fresenius, Bad Homburg, Germany) was used to separate 2.0 × 10 9 PBMCs containing leukaemic blasts; 10 ml of autologous plasma was also collected. The PBMCs were split into two batches to enrich for DCs and CIK cells separately, as described below, in a good manufacturing practice certified standard laboratory.
The first batch of PBMCs containing leukaemic blasts was used to enrich DCs by adding to a six-well plate with X-VIVO™ 20 serum-free medium (BioWhittaker, Shanghai, China) with 80 mg/ml gentamycin (Invitrogen, Shanghai, China) at a cell density of 2.5 × 10 6 cells/ml. Then, 1000 IU/ml GM-CSF, 100 IU/ml interferon (IFN)-α (Cell Concepts, Umkirch, Germany), 100 ng/ml FLT-3 ligand (PromoCell, Bad Homburg, German), 50 IU/ml stem cell factor (Cell Concepts), and 0.25 ng/ml transforming growth factor (TGF)-β (Cell Concepts) were added and cells were cultured at 37°C in 5% carbon dioxide. The medium was replaced once and the growth factors were supplemented every 3 -4 days. The DCs were collected on day 8 of culture, as described previously, 13 and a cell counting chamber (Shanghai Xin An Import & Export Co. Ltd, Shanghai, China) was used to count the cells. 14 15 the culture was considered successful. Cells were placed in the refrigerator at −80°C until needed for transfusion.
The second batch of PMBCs was used separately to enrich for CIKs. Dendritic and cytokine-induced killer cells in immunotherapy in AML Immunomagnetic beads (Guangzhou Genewindows Biotech. Co Ltd, Guangzhou, China) were used to remove leukaemic blasts and acquire CD3 + T cells which were then cultured in X-VIVO™ 20 serum-free with 80 mg/ml gentamicin at a cell density of 5 × 10 6 cells/ml at 37°C in 5% carbon dioxide. Then, 1000 IU/ml IFN-γ (Cell Concepts) was added and, after incubating for 24 h at 37°C, 50 ng/ml of the anti-CD3 monoclonal antibody Orthoclone (OKT)-3 (Wuhan Institute of Biological Products Co. Ltd, Wuhan, China) and 300 IU/ml interleukin (IL)-2 (Cell Concepts) were added. The medium was replaced every 3 -4 days. Up to 300 IU/ml IL-2 was supplemented every 6 -7 days. The counting chamber, referred to above, was used to count cells after 21 days of incubation, as described for the generation of CIK cells by Linn et al. 6 
LOW-DOSE CHEMOTHERAPY PROTOCOL
Patients in the immunotherapy group were started on low-dose chemotherapy (14-day course) immediately after collecting the PMBCs; i.e. at the same time that autologous DC and CIK cell culture was started. After blood collection, patients in both the immunotherapy and control groups received a single course of the following chemotherapy regimen (low-dose HAG): 200 µg/m 2 GM-CSF by subcutaneous (s.c.) injection once daily for 14 days; 10 mg/m 2 cytosine arabinoside by s.c. injection every 12 h for 14 days; and 1 mg/day homoharringtonine by intravenous (i.v.) injection every day for 14 days.
TRANSFUSION PROTOCOL FOR DCS AND CIK CELLS
On day 7 after completion of chemotherapy (day 21), combined transfusion of DCs and CIK cells was carried out in the immunotherapy group in the absence of any obvious bacterial, fungal, endotoxin, or mycoplasma infection. The DCs were thawed and added to CIK cells which had been in culture for 21 days. Patients in the immunotherapy group received a total mean ± SD of 7.36 ± 0.48 × 10 7 DCs and 5.47 ± 1.3 × 10 9 CIK cells by i.v. transfusion, at a rate of 0.3 ml/min over 30 min once daily on each of 5 days. Each day, one-fifth of the total cells were suspended in 100 ml normal saline and 6 -10 ml of autologous plasma from the patients was added; a fresh suspension was made on each of the 5 days.
CLINICAL CURE STANDARD
Clinical efficacy and quality of life were evaluated after the completion of treatment. Remission was assessed based on the 2009 clinical criteria of the NCCN for AML. The clinical cure standard for the patients in the two groups was the total effect rate, i.e. complete remission (CR) rate + partial remission (PR) rate. CR was defined as the patient achieving a morphologically leukaemia-free state and absolute neutrophil count > 1000 cells/µl, platelet count of 100 000 cells/µl, and no residual evidence of extramedullary disease. PR was defined as a decrease of at least 50% in the percentage of blasts to 5 -25% of the bone marrow aspirate and the normalization of blood cell counts. After treatment, if none of the above criteria was observed, patients were defined as having no remission (or disease progression). Cytogenetic risk stratification, based on the chromosome profile of the patients, was used to evaluate prognosis. Quality of life was evaluated using the Karnofsky scoring system. 16 Before and after the infusion of DCs with CIK cells, an electrocardiogram was carried out, and liver and kidney functions were tested. Adverse events were collected by clinical observation and patient report throughout the study.
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Blood samples were taken from patients in the immunotherapy group before the start of immunotherapy on day 1 and on day 7 after the transfusion of DC and CIK cells. Peripheral venous blood (5 ml) was collected from each patient after fasting for ≥ 6 h and was placed into sterile heparinized anticoagulant tubes (NVIDIA Technology Co. Ltd, Beijing, China). The percentages of CD3 + , CD3 + CD4 + , CD3 + CD56 + and CD3 + CD8 + T cells were examined by flow cytometry (FACSCalibur™) using FITClabelled anti-CD3 and anti-CD56, phycoerythrin-labelled anti-CD8, allophycocyanin-labelled anti-CD4 and peridinin-chlorophyll-protein complexlabelled anti-CD45 monoclonal antibodies (Immunotech). The mean ± SD percentage of each T cell subset was calculated as a percentage of the total number of lymphocyte subsets.
Another 5 ml of venous blood was collected and placed into sterile heparinized anticoagulant tubes as described above. Plasma levels of IL-12, IL-2, IL-7, IFN-γ and tumour necrosis factor (TNF)-α were determined by enzyme-linked immunosorbent assay (ELISA) using the appropriate biotinylated antibodies (Labsystems, Shanghai, China) and measuring at a wavelength of 450 nm using a MK3 ELISA analyser (Labsystems) according to the manufacturer's instructions.
STATISTICAL ANALYSES
The SPSS ® statistical package, version 17.0 (SPSS Inc., Chicago, IL, USA) was used to process the data, which were expressed as mean ± SD or number (percentage) of patients. The Student's t-test was used to analyse continuous data and the χ 2 -test was used to compare numerical data between the immunotherapy and control groups. A Pvalue < 0.05 was considered to be statistically significant.
Results
A total of 44 elderly patients with AML were included in the study: 21 in the immunotherapy group and 23 in the control group. The baseline characteristics of the patients in the two groups are shown in Table 1 .
The mean ± SD percentages of CD3 + , CD3 + CD4 + , CD3 + CD8 + and CD3 + CD56 + cells in patients after immunotherapy with DCs and CIK cells (day 7 after start of treatment) were significantly increased compared with before treatment (day 1) (P < 0.05 for all comparisons; Table 2 ). Levels of IL-12, IL-2, IL-7, IFN-γ and TNF-α in the patients after treatment (day 7) were significantly increased compared with before treatment (P < 0.05 for all comparisons; Table 3 ).
The total effect rate in the immunotherapy group (CR + PR) was significantly higher than that in the control group (P = 0.032; Table 4 ). In the immunotherapy group, one patient classified with a poor prognosis reached PR, the other three patients classified with a poor prognosis had disease progression. In the control group, all six patients classified with a poor prognosis had disease progression; two died within 2 weeks of completion of chemotherapy. Following treatment, in the immunotherapy group the mean ± SD Karnofsky score was significantly higher (71.90 ± 12.09) than in the control group (60.00 ± 23.39) (P = 0.042).
Adverse events resulting from the transfusion of DCs and CIK cells included eight cases of feeling cold, five cases of myalgia and seven cases of noninfective fever. Generally, noninfective fever lasted 4 -7 h and body temperature was 37.5 -38.5°C.
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These adverse events were observed only in the immunotherapy group and occurred in the initial 48 h after receiving treatment. They were regarded as being related to the Data presented as mean ± SD or number of patients. a Cytogenetic risk, an evaluation of patient prognosis based on the chromosome profile of patients with acute myeloid lymphoma. b NS, no statistically significant between-group difference (P ≥ 0.05). immunotherapy treatment. No adverse events were observed in the control group. All adverse events in the immunotherapy group were relieved with symptomatic treatment. There was no change before and after transfusion in electrocardiogram, liver and kidney functions.
TABLE 1: Characteristics at study entry of elderly patients diagnosed with acute myeloid lymphoma prior to receiving treatment with dendritic cells and cytokine-induced killer cells plus lowdose chemotherapy (immunotherapy group) or low-dose chemotherapy only (control group)
TABLE 2: Comparison of T cell subsets as a percentage of the total number of each subset in peripheral blood from elderly patients diagnosed with acute myeloid lymphoma before and after 7 days of treatment with dendritic cells and cytokine-induced killer cells plus low-dose chemotherapy (immunotherapy group) T cell subset
Discussion
Acute myeloid leukaemia is a common haematological therioma in elderly people. Due to poor prognosis, general conditions are poor and various complications occur, which leads to lack of tolerance to high-dose chemotherapy and HSCT. In elderly patients with AML, low-dose chemotherapy or supportive treatment is mainly used and HAG is one example of this type of treatment. 17 Chemotherapy-related adverse events tend to be minimal and the immune system is not adversely affected by such treatment. The present study investigated the clinical efficacy and adverse events of immunotherapy with cultured DCs and CIK cells, obtained at initial diagnosis of AML in elderly patients, administered in combination with low-dose HAG chemotherapy. The DCs are important APCs that are highly positive for major histocompatibility complex (MHC) and various costimulatory molecules and that can activate effector T cells, especially toxic T cells of tumour cells. DCs are stimulated by tumour-associated peptides/antigens 18 and leukaemia-derived DCs can be generated in vitro by converting leukaemic cells directly into mature APCs, giving rise to leukaemic cells coexpressing DC-typical antigens. 19 Some researchers have successfully cultured DCs from AML patients, including elderly patients with AML, and have shown that they highly expressed various costimulatory and MHC molecules and induced effector T cells in bone marrow. 20, 21 In the present study, various cytokines such as GM-CSF, IFN-α, FLT-3, stem cell factor and TGF-β were added to PBMCs containing leukaemic blasts for 8 days to enrich for DCs. Inverted microscopy observations showed that PBMC had the morphological characteristics of DCs. If the number of CD83 + cells, which indicates mature DCs, was ≥ 10%, the culture was considered successful; 15 PMBCs from all the 21 elderly patients with AML used for this procedure were successfully enriched for DCs in the present study.
The CIK cells are polyclonal effector T cells. Some studies have successfully cultured CD3 + cells, taken from patients at initial diagnosis of leukaemia, into CIK cells which dissolved autologous or allogeneic leukaemia target cells. 22, 23 In the present study, purified CD3 + cells were successfully cultured into CIK cells.
In terms of numbers of cells and oncolytic activity, cultured CIK cells have been shown to be the same as the CIK cells of healthy donors and AML patients in recovery after chemotherapy. 22 The present study used PBMCs that were extracted at initial diagnosis from elderly patients with AML, and immunomagnetic beads were used to remove leukaemic blasts. After adding IFN-γ, OKT-3 and IL-2, the purified CD3 + T cells were cultured for 21 days, showing that it is possible to culture CIK cells obtained at diagnosis from elderly patients with AML. Some reports have demonstrated that DCs promote the secretion of the type 1 helper T cell (Th1) cytokine IL-12. 24 Other reports have demonstrated that the CD3 + CD56 + T cell subset is positive for high levels of IL-7R, IL-12Rβ 2 , IFN-γ, TNF-α, TGF-β 1 , and caspase-1, 25 and that CIK cells can also secrete a large number of Th1 type cytokines (IL-2, IL-12, IFN-γ and TNF-α), which promote sensitivity of tumour cells to the CIK cell killing effect. The present study showed that the percentages of CD3 + , CD3 + CD56 + , CD3 + CD4 + and CD3 + CD8 + T cells in patients with AML after transfusion of DCs and CIK cells were significantly higher than before treatment. The significant increase of CD3 + CD4 + T cells was possibly associated with DC induction of CD4 + T-cells. The increase of CD3 + CD8 + T cells was possibly associated with CD3 + CD56 + T cells being simultaneously positive for CD8 + . Moreover, the current study demonstrated that the levels of IL-12, IL-2, IL-7, IFN-γ and TNF-α in the patients after treatment with DCs and CIK cells increased to different extents. The increase of IL-12 was important in that it was possibly associated with both DC-and CIK-promoted secretion of IL-12.
The DCs can recognize antigens and activate the acquired immune system. CIK cells kill tumour cells by acting on autologous cytotoxicity and cytokine-secreting cells. One clinical trial showed that treatment with DCs and CIK cells enhanced the clinical efficacy of conventional chemotherapy in patients with advanced nonsmall cell lung cancer. 26 Immune function is suppressed in patients with leukaemia who receive conventional chemotherapy. Thus, if DCs are administered concomitantly with conventional chemotherapy, they are unable to induce an antitumour T cell effect. In previous studies, 10, 11 venous transfusion of DCs and CIK cells was performed after complete haematological remission. To avoid the adverse effects of chemotherapy on DCs, in the present study, enriched DCs were frozen after day 8 of culture, then thawed and administered on day 7 after completion of chemotherapy. Although some DCs were lost during the freezing and thawing process, this process was still considered to be more effective than administering DCs before or during chemotherapy.
There were several limitations to the present study. For example, the control group did not receive a placebo infusion and levels of cytokines or T cells were not measured in the control group to compare with the immunotherapy group. In addition, this was not a randomized or blinded study but received immunotherapy based on their choice and ability to cover healthcare costs. Randomized, controlled studies are required to verify these data.
In conclusion, the present study showed that immunotherapy with autologous DCs and CIK cells significantly increased immunity, as measured by levels of cytokines and T-cells before versus after treatment in elderly patients with AML when given with conventional chemotherapy. To the best of our knowledge this is the first time that the clinical efficacy of a combination of DCs and M Dong, D Liang, Y Li et al.
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CIK cells with low-dose chemotherapy to treat AML in elderly patients has been reported. Additionally, we believe it is the first time that the transfusion of DCs combined with CIK cells has been carried out before achieving CR through chemotherapy. All adverse events that occurred in response to immunotherapy were relieved with symptomatic treatment. The results suggest that treatment with autologous DC and CIK cells in combination with low-dose chemotherapy in elderly patients with AML is a promising mode of treatment.
